Resolve Therapeutics and Institut Pasteur de Montevideo today announce a collaboration to use REJOIN-seq to identify the cell-free RNA (cfRNA) molecules that drive cytokine production and inflammation in autoimmunity.
Resolve Therapeutics, a next-generation biopharma company transforming the treatment of autoimmune diseases with innovative non-immunosuppressive drugs (Resolve Therapeutics) and the Institut Pasteur de Montevideo, the premier basic science laboratory at the forefront of cfRNA in human disease (pasteur.uy), will collaborate to identify the central upstream triggers that drive inflammation in autoimmune disease.
Damaged, modified self-RNA and endogenous retroviral RNA molecules circulating in the blood are the most proximal triggers of a self-perpetuating inflammatory cascade present in diseases such as lupus and Sjögren’s. Because these molecules are inherently fragile, they are not captured using conventional sequencing methods, resulting in the loss of critical disease-related information. REJOIN-seq is an innovative new technology developed at the Pasteur that restores and repairs partially degraded cfRNA, enabling the sequencing of molecules that have heretofore been lost with conventional sequencing.
“Embedding Pasteur’s next generation RNA-seq technology within Resolve’s clinical programs provides a unique opportunity to significantly advance our understanding of cfRNA in autoimmune diseases,” commented Dr. James Posada chief executive officer of Resolve Therapeutics. “Pasteur’s Dr.Tosar has published some of the most careful, exacting science in the field of cfRNA, we are thrilled to work with his team” added Dr. Posada.
“We are confident that combining our next generation REJOIN-seq technology with Resolve’s clinical programs will unlock information regarding the upstream events that trigger the inflammatory cascade in autoimmunity” commented Dr. Juan Tosar, chief of functional genomics at the Pasteur.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
